Dermata Therapeutics, Inc. Warrant
DRMAWStock
$0.01
Market Cap—
P/E—
Div yield—
Beta1.49
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-39.41%
Price vs S&P 500 (4W)-12.55%
VGM Score27.25
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DRMAWDermata Therapeutics, Inc. Warrant | — | — | D | $0.01 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Dermata Therapeutics develops over-the-counter dermatology products for acne, psoriasis, rosacea, and seborrheic dermatitis. The company is advancing a once-weekly acne treatment combining an OTC-approved active ingredient with its proprietary Spongilla delivery technology. Dermata intends to expand the Spongilla platform across multiple dermatologic and aesthetic applications, including intradermal botulinum toxin delivery.